Table 2.
Variable | Baseline Mean±SD | Post-intervention Mean±SD |
Mean Difference [95% CI] |
Range of Mean Difference |
% change | P-values |
---|---|---|---|---|---|---|
F2-isoprostanes, ng/mg creatinine | ||||||
iPF(2-alpha)-III | 0.15 ± 0.13 | 0.24 ± 0.22 | +0.09 [−0.02 to 0.19] | −0.140 to 0.77 | +55% | 0.10 |
2,3-dinor-iPF(2 alpha)-III | 3.05 ± 2.67 | 3.63 ± 4.02 | +0.59 [−1.96 to3.13] | −5.49 to 16.85 | +19% | 0.60 |
iPF (2-alpha)-VI | 2.85 ± 1.33 | 3.66 ± 2.12 | +0.81 [0.06 to 1.57] | −1.79 to 3.07 | +29% | 0.04 |
8,12-iso-iPF(2alpha)-VI | 2.12 ± 1.25 | 2.71 ± 1.84 | +0.59 [−0.06 to 1.23] | −0.86 to 2.62 | +28% | 0.07 |
Composite Index* | 1.61 ± 0.90 | 2.12 ± 1.33 | +0.51 [−0.08 to 1.10] | −0.81 to 3.49 | +32% | 0.08 |
Composite index was calculated as each value was standardized (divided by the standard deviation for a corresponding biomarker at the corresponding time point), mean standardized value for four markers was calculated for each participant at baseline and post-intervention.